Karina Winiarskyj Email

Associate Director, MSAT and CMC Program Management . Strand Therapeutics

Current Roles

Employees:
131
Revenue:
$20.3M
About
Strand was started by biological engineers working together at MIT. Building on the idea of creating smart therapies that are capable of making sophisticated decisions, they sought to apply the concept of the emerging field of mRNA therapeutics. This area was untapped by traditional synthetic biology, which led them to build their own mRNA “programming language,” creating the world's first platform for mRNA smart therapies. Strand's mRNA programming technology promises to make mRNA therapies safer and more effective by programming the location, timing, and intensity of therapeutic protein expression inside a patient's body using mRNA-encoded logic circuits. These circuits can implement cell-type specific expression by sensing and classifying the unique miRNA expression signatures of cells, as well as controlling the dosage of protein expression by responding to exogenously administered small molecules.
Strand Therapeutics Address
20 Overland Street
Cambridge, MA
United States
Strand Therapeutics Email

Past Companies

Strand TherapeuticsAssociate Director, MSAT and CMC Program Management
Strand TherapeuticsPrincipal Scientist, mRNA Process Development
ModernaScientist, Process Development

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.